Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
J Natl Compr Canc Netw. 2012 Feb;10(2):213-24; quiz 225. doi: 10.6004/jnccn.2012.0020.
Most patients with colon cancer are older than 65 years. Their treatment poses multiple challenges, because they may have age-related comorbidities, polypharmacy, and physical or physiologic changes associated with older age. These challenges include limited data on the ability to predict tolerance to anticancer therapy and the appropriate use of treatment modalities in the setting of comorbidity and concurrent frailty. The low number of older patients enrolled in large clinical trials results in a paucity of evidence to guide oncologists in the appropriate management of this population. In early-stage disease, clinical dilemmas arise regarding the ability of older patients to undergo successful curative surgical procedures and the risk/benefit ratio of adjuvant chemotherapy. The management of metastatic disease raises questions regarding the clinical benefit of various anticancer therapies and the role of combination therapy with possible increased toxicity in the noncurative setting. Overall, the available evidence shows that fit older patients are able to tolerate treatment and derive similar clinical benefits to younger patients. Limited data are available to guide treatment for less-fit, more-vulnerable older patients. This lack of data leads to variations in treatment patterns in older adults, making them less likely to receive standard therapies. This review provides an overview of the available data regarding the management of older adults with colon cancer in the adjuvant and metastatic settings.
大多数结肠癌患者年龄超过 65 岁。他们的治疗带来了多种挑战,因为他们可能有与年龄相关的合并症、多种药物治疗和与年龄相关的身体或生理变化。这些挑战包括:预测抗癌治疗耐受性的能力的数据有限,以及在合并症和同时存在衰弱的情况下适当使用治疗方式。在大型临床试验中,老年患者的数量较少,导致缺乏证据来指导肿瘤学家对这一人群进行适当的管理。在早期疾病中,关于老年患者是否能够成功接受根治性手术以及辅助化疗的风险/获益比的临床难题出现了。转移性疾病的管理提出了关于各种抗癌疗法的临床获益以及在非治愈性环境中联合治疗可能增加毒性的作用的问题。总的来说,现有证据表明,健康的老年患者能够耐受治疗并获得与年轻患者相似的临床获益。对于身体状况较差、更为脆弱的老年患者,可用的数据有限,无法为其治疗提供指导。这种数据的缺乏导致了老年患者治疗模式的差异,使他们不太可能接受标准治疗。这篇综述提供了关于辅助治疗和转移性结肠癌老年患者管理的现有数据概述。